Angela Maerten Clinical Oncology Society of Australia Annual Scientific Meeting 2018

Abstracts this author is presenting:

• Afatinib for patients with EGFR mutation-positive (EGFRm+) NSCLC: activity in patients with baseline brain metastases and impact on the rate of central nervous system (CNS) progression or spread — Poster Session 2
• Afatinib in patients with EGFR mutation-positive (EGFRm+) NSCLC harbouring uncommon mutations: experience in ‘real-world’ clinical practice — Poster Session 2
• Impact of afatinib dosing on safety and efficacy in patients with EGFR mutation-positive advanced Non-Small Cell Lung Cancer (NSCLC) in a real-world setting — Poster Session 2